Eli Lilly and Company

M Brian Arnold

Paul Leslie Ornstein

William H Lunn

Darryle D Schoepp

Nancy K Augenstein

Michael J Martinelli

David R Helton

Bret E Huff

Thomas John Bleisch

Marvin M Hansen

Mary Jeanne Kallman

Joseph P Tizzano

Allen R Harkness

Carl F Bertsch

The present invention provides compounds of formula ##STR1## in which R represents an organic group, or a pharmaceutically acceptable metabolically labile ester or amide thereof, or a pharmaceutically acceptable salt thereof, which are useful as antagonists of one or more of the actions of L-glutamate at metabotropic excitatory amino acid receptors.

Excitatory amino acid receptor antagonists

This invention provides novel decahydroisoquinoline compounds which are useful as excitatory amino acid receptor antagonists and in the treatment of neurological disorders. This invention also provides synthetic methods for preparing decahydroisoquinolines, as well as, novel intermediates in the synthesis thereof.

Process for preparing isoquinoline compounds

Isoquinolinyl compounds which are intermediates

Growing community of inventors

Franklin, IN, United States of America

M Brian Arnold